Drug intelligence / Profile preview

ammonium undecylenate

Development stage: Preclinical
Lead developer: Wintermute Biomedical
Modality: Small Molecules
Administration: Topical

Overview

Ammonium undecylenate is a topical antibacterial agent being developed by Wintermute Biomedical. It is the ammonium salt of undecylenic acid, a fatty acid with known antifungal and antibacterial properties. The compound is specifically designed to target Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA), and is currently in preclinical development for the treatment of impetigo and other antibiotic-resistant skin infections. Its mechanism of action involves the disruption of bacterial cell membranes, providing a potential alternative to traditional antibiotics for resistant dermatological conditions.

Other names: ammonium carboxylate salt of undecylenic acidammonium undec-10-enoate

Beyond the preview

Go deeper on ammonium undecylenate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ammonium undecylenate.

Explore the full profile